Vader Justin M, LaRue Shane J, Stevens Susanna R, Mentz Robert J, DeVore Adam D, Lala Anuradha, Groarke John D, AbouEzzeddine Omar F, Dunlay Shannon M, Grodin Justin L, Dávila-Román Victor G, de las Fuentes Lisa
Washington University School of Medicine, St. Louis, Missouri.
Washington University School of Medicine, St. Louis, Missouri.
J Card Fail. 2016 Nov;22(11):875-883. doi: 10.1016/j.cardfail.2016.04.014. Epub 2016 Apr 28.
Readmission or death after heart failure (HF) hospitalization is a consequential and closely scrutinized outcome, but risk factors may vary by population. We characterized the risk factors for post-discharge readmission/death in subjects treated for acute heart failure (AHF).
A post hoc analysis was performed on data from 744 subjects enrolled in 3 AHF trials conducted within the Heart Failure Network (HFN): Diuretic Optimization Strategies Evaluation in Acute Heart Failure (DOSE-AHF), Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARRESS-HF), and Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE-AHF). All-cause readmission/death occurred in 26% and 38% of subjects within 30 and 60 days of discharge, respectively. Non-HF cardiovascular causes of readmission were more common in the ≤30-day timeframe than in the 31-60-day timeframe (23% vs 10%, P = .016). In a Cox proportional hazards model adjusting a priori for left ventricular ejection fraction <50% and trial, the risk factors for all-cause readmission/death included: elevated baseline blood urea nitrogen, angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) non-use, lower baseline sodium, non-white race, elevated baseline bicarbonate, lower systolic blood pressure at discharge or day 7, depression, increased length of stay, and male sex.
In an AHF population with prominent congestion and prevalent renal dysfunction, early readmissions were more likely to be due to non-HF cardiovascular causes compared with later readmissions. The association between use of ACEI/ARB and lower all-cause readmission/death in Cox proportional hazards model suggests a role for these drugs to improve post-discharge outcomes in AHF.
心力衰竭(HF)住院后的再入院或死亡是一个重要且受到密切关注的结果,但风险因素可能因人群而异。我们对接受急性心力衰竭(AHF)治疗的患者出院后再入院/死亡的风险因素进行了特征描述。
对心力衰竭网络(HFN)开展的3项AHF试验中纳入的744例受试者的数据进行了事后分析:急性心力衰竭利尿剂优化策略评估(DOSE-AHF)、急性失代偿性心力衰竭的心肾挽救研究(CARRESS-HF)以及急性心力衰竭肾优化策略评估(ROSE-AHF)。分别有26%和38%的受试者在出院后30天和60天内发生全因再入院/死亡。再入院的非HF心血管原因在≤30天时间范围内比在31 - 60天时间范围内更常见(23%对10%,P = 0.016)。在一个预先对左心室射血分数<50%和试验进行调整的Cox比例风险模型中,全因再入院/死亡的风险因素包括:基线血尿素氮升高、未使用血管紧张素转换酶抑制剂(ACEI)/血管紧张素受体阻滞剂(ARB)、基线血钠降低、非白人种族、基线碳酸氢盐升高、出院时或第7天收缩压降低、抑郁、住院时间延长以及男性。
在一个有明显充血和普遍肾功能不全的AHF人群中,与后期再入院相比,早期再入院更可能是由于非HF心血管原因。Cox比例风险模型中ACEI/ARB的使用与较低的全因再入院/死亡之间的关联表明这些药物在改善AHF患者出院后结局方面具有作用。